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Introduction: The use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) scanning for
baseline staging and assessment of treatment response for higher grade lymphomas is considered to be the
standard of care. Evaluation of lymphomatous bone marrow infiltration on 18F-FDG PET can usually distinguish
between normal regenerating marrow following chemotherapy by a characteristic pattern of uptake.
Case presentation: Here we report the case of a 51-year-old Caucasian woman with mixed low- and high-grade
lymphoma with biopsy confirmed marrow infiltration. An interim post-three cycle chemotherapy 18F-FDG PET scan
revealed apparent progression of marrow disease. Subsequent investigations were performed including bone
marrow biopsies, repeat 18F-FDG PET scanning and a white cell scan. These revealed the interim 18F-FDG PET scan
appearance was due to a highly unusual pattern of scattered islands of regenerating normal marrow, rather than
progressive lymphoma.
Conclusions: Our case report highlights that apparent severe bone marrow abnormalities on 18F-FDG PET scans in
lymphoma patients treated with chemotherapy are not always due to disease. Clinicians should retain a high
index of suspicion for benign causes when 18F-FDG PET scan results appear incongruent with clinical
response.
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The use of 18F-fluorodeoxyglucose positron emission
tomography (18F-FDG PET) scanning for baseline sta-
ging and assessment of treatment response for higher
grade lymphomas is considered standard of care [1,2], and
in many institutions has replaced diagnostic computed
tomography (CT) as the imaging modality of choice for
this condition. There is overwhelming evidence in the lit-
erature demonstrating the powerful prognostic utility of
18F-FDG PET with higher grade lymphoma patients who* Correspondence: m.cherk@alfred.org.au
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unless otherwise stated.have a persistently positive interim mid-treatment (post-
two or three cycles of chemotherapy) PET scan for disease
having a significantly worse prognosis compared to those
who achieve complete metabolic remission [3-5]. As a
result, many clinical trials are currently being conducted
to evaluate whether a change or intensification in therapy,
such as stem cell transplantation in patients with a posi-
tive interim PET scan, confers survival benefit [6-8].
Although spurious results can occur due to cellular
uptake of 18F-FDG not being specific to lymphoma or
malignancy, a false positive finding on interim PET scan-
ning is generally low and in equivocal cases can often be
resolved with tissue sampling and histological correlation.
18F-FDG PET scanning is quite sensitive for detecting
bone marrow involvement in higher grade lymphomastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of increased marrow activity within the skeleton [9,10].
In contrast, physiologic reactive marrow, which is often
seen following blood loss, sepsis or shortly after chemo-
therapy, is usually depicted by diffuse relatively uniform
increased FDG uptake throughout the axial and prox-
imal appendicular skeleton [11].
Case presentation
In February 2013, a 51-year-old Caucasian woman pre-
sented with a several month history of back pain, hot
flushes, sweats and weight loss. A subsequent CT scan
demonstrated multiple enlarged cervical nodes, as well as
confluent paravertebral soft tissue masses in the region of
the thoracic spine and anterior to L5 to the presacral re-
gion. A CT-guided core biopsy of the presacral mass was
performed and histology confirmed low grade B-cell non-
Hodgkin lymphoma based on immunostaining results.
Further staging included a whole body 18F-FDG PET
scan which demonstrated moderate to markedly FDG-
avid right upper and bilateral lower thoracic para-spinal,
lower lumbar para-spinal and presacral soft tissue masses
with extension into several right lower lumbar and sacralFigure 1 Three-dimensional maximal intensity projection 18F-fluoro
Baseline prior to treatment (A), after three cycles of chemotherapy (B)neural foramen. Heterogeneous increased FDG uptake
was also seen in a right external iliac node and throughout
the skeleton, most marked and intense in the trochanteric
region of the right femur and right ilium, consistent with
marrow infiltration (Figure 1A). A bone marrow aspirate
and trephine of the right ilium at a site of increased FDG
uptake on the PET scan confirmed a marrow packed with
lymphoma, with a combination of small and larger cells,
the latter of which were CD20 positive. Due to sacral
and lumbar neural foramen invasion, CT and magnetic
resonance imaging (MRI) brain scans along with a lumbar
puncture were performed to exclude leptomeningeal dis-
ease. These were found to be negative.
Despite the presacral mass core biopsy demonstrating
low grade B-cell small lymphocytic lymphoma, clinical
symptoms, bone marrow biopsy and 18F-FDG PET scan
findings were suggestive of concomitant higher grade
lymphoma. She was thus considered likely to have fol-
licular B-cell lymphoma with high-grade transformation
and treatment comprised of six cycles of cyclophospha-
mide, doxorubicin, vincristine, prednisolone and rituxi-
mab (CHOP-R) chemotherapy with pegfilgrastim support
every three weeks. This was followed by two cycles ofdexoyglucose positron emission tomography scan images.
and at completion of six cycles of chemotherapy (C).
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for central nervous system disease from direct neural
foramen invasion.
The first three cycles of CHOP-R chemotherapy were
well-tolerated without significant complication apart
from persistent low-grade lower back pain. An interim
mid-treatment 18F-FDG PET scan to assess treatment re-
sponse was performed at this point which demonstrated
resolution of FDG-avid right upper and bilateral lower
thoracic para-spinal, lower lumbar para-spinal and pre-
sacral soft tissue masses and right external iliac node
(Figure 1B). FDG uptake in the trochanteric region of
the right femur and right ilium had also decreased, how-
ever, new heterogeneous intense FDG uptake was dem-
onstrated throughout most of the axial and proximal
appendicular skeleton, sternum and numerous ribs. SomeFigure 2 Midline sagittal positron emission tomography scan images
bone marrow of the spine. Baseline prior to treatment (A), after three cy
chemotherapy (C).of this corresponded with mixed lytic and sclerotic lesions
on the fusion low-dose CT scan performed at the time of
the 18F-FDG PET scan which was highly suggestive of
widespread high-grade lymphoma progression within the
marrow (Figures 1B and 2B).
A right posterior superior iliac spine bone marrow
biopsy was thus performed with a view to intensifying
chemotherapy if persistent lymphoma was confirmed
within the marrow. This was performed at a site previously
positive for marrow involvement on the pretreatment PET
scan, and demonstrated a moderately hypocellular marrow
with some clusters of B-cells, which may have been regen-
erative in nature. No convincing evidence of residual
lymphoma was seen. Given the suspicious PET scan find-
ings and potential patchy nature of disease, a repeat bone
marrow biopsy was performed from the left posteriorhighlighting pattern of 18F-fluorodexoyglucose uptake in
cles of chemotherapy (B) and at completion of six cycles of
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dence of lymphoma and normal moderately hypercel-
lular tri-lineage hemopoiesis.
As residual lymphoma was not confirmed on both
bone marrow biopsies, treatment was not changed and
she completed a further three cycles of CHOP-R chemo-
therapy, at which point another 18F-FDG PET scan was
performed (Figures 1C and 2C). This scan again demon-
strated a similar heterogeneous pattern of increased
FDG uptake throughout the marrow of the skeleton in a
similar distribution to the post third cycle interim PET
scan however, overall intensity of uptake had decreased
significantly and was not typical for disease progression.
Due to the apparent improvement in PET scan ap-
pearances, a whole body radiolabelled white cell scan
was performed to evaluate normal skeletal bone marrow
activity. This demonstrated areas of normal marrow activ-
ity throughout the skeleton in a similar highly heteroge-
neous distribution to the interim and post-six cycle PET/
CT scans. This suggested that the apparent ‘abnormal’
bone marrow appearance on the interim and, to a lesser
extent, post-six cycle chemotherapy PET scans actually
represented FDG uptake in scattered residual islandsFigure 3 Comparison of 18F-fluorodexoyglucose positron emission to
marrow activity on whole body white cell scan post six cycles of chem
posterior planar view (C) three-dimensional maximal intensity projection (M
PET scan is similar to the white cell scan uptake in keeping with sites of no
similarities in FDG and white cell uptake in the thoracic and lumbar spine.of regenerating and pegfilgrastim-stimulated normal
bone marrow, rather than sites of progressive lymph-
oma (Figure 3).
Our patient has remained in clinical remission for three
months since the post-six cycle chemotherapy PET scan,
and continues to receive three-monthly rituximab main-
tenance therapy for the presumed lower grade lymphoma
component of her disease.
The baseline, interim and completion PET scans were
all performed on the same Phillips GEMINI PET/CT cam-
era (Phillips Healthcare, Massachusetts, United States).
The range of 18F-FDG dose and uptake time for the
three PET/CT scans were 307 to 319 MBq and 60 to 65
minutes, respectively, suggesting differences between
PET scan appearances were true changes and not due to
variability in the acquisition technique.
Discussion
This case highlights assessment of treatment response in
bone marrow on PET scanning can be confounded in
cases where the lymphoma has caused significant disrup-
tion to normal marrow architecture, resulting in islands
of normal residual rapidly regenerating marrow givingmography scan uptake in spine with sites of normal bone
otherapy. White cell scan anterior planar view (A), White cell scan
IP) 18F-FDG PET scan images (B). The overall pattern of FDG uptake on
rmal regenerating marrow rather than lymphoma. Arrows highlight
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bone marrow scan, in this case a white cell scan, is useful
in discriminating between bone marrow regeneration and
progressive disease by the degree of its congruence with
the FDG PET study.
Our case is unusual as the focal increased marrow and
bony FDG uptake in the trochanteric region of the right
femur and right ilium was consistent with disease in-
volvement on the baseline pretreatment PET scan. FDG
uptake in the remainder of the skeleton appeared rela-
tively normal despite mixed lytic and sclerotic lesions
scattered throughout the skeleton on CT. The lack of
FDG-avidity at these sites suggested an underlying lower
grade lymphoma, with the more FDG-avid sites repre-
senting sites of transformed higher grade disease. The
interim post-three cycle chemotherapy PET scan was
most concerning for a mixed response to therapy, with
the new highly heterogeneous appearance in the marrow
being suspicious for disease progression despite meta-
bolic resolution of the femoral and ilial bone lesions and
sites of nodal disease.
The typical normal reactive marrow appearance seen
following chemotherapy is that of diffusely increased
relatively uniform FDG uptake throughout the marrow
[11]. In patients with malignant marrow infiltration or
bone involvement, successfully treated areas usually ap-
pear photopenic or inactive on follow-up PET scans. This
can result in a heterogeneous appearance where sites of
successfully treated lymphoma which appear photopenic
are interspersed with islands of more FDG-avid regenerat-
ing normal marrow. This ‘flip-flop’ phenomenon on PET
scan has been previously described in cases of high-grade
lymphoma [12,13]. In most cases of lymphomatous
involvement of bone or bone marrow, the heteroge-
neous appearance on post-therapy PET scans can usu-
ally be reconciled from being malignant in nature by
carefully comparing pre- and post-treatment PET scan
appearances [14].
As our patient likely has mixed low- and high-grade
lymphoma, the interim and post-therapy PET/CT scan
appearances possibly represent a partial flip-flop variant,
with photopenic sites representing either sites of suc-
cessfully treated disease or non FDG-avid less chemo-
therapy responsive lower grade lymphoma.
A further likely contributing factor in this case is the
timing of PET scanning post-pegfilgrastim administra-
tion. The post-three cycle interim PET scan was per-
formed four days following pegfilgrastim administration.
At this time point, pegfilgrastim was likely having its max-
imal stimulatory effect on granulopoiesis, resulting in any
residual islands of normal bone marrow appearing par-
ticularly FDG-avid, further mimicking disease progression
in the marrow [15,16]. In contrast, the post-six cycle
chemotherapy PET scan was performed 17 days followingpegfilgrastim administration, a time point where pegfil-
grastim effects would have subsided resulting in any re-
sidual islands of normal bone marrow appearing less
FDG-avid. The findings of this post-six cycle PET study
showed strong concordance with the subsequently per-
formed white cell scan, with the distribution and intensity
marrow lesions now being essentially equivalent.
Conclusions
Apparent new focal bone marrow abnormalities on PET
scans in lymphoma patients treated with chemotherapy
and pegfilgrastim are not always due to progressive dis-
ease. Clinicians should retain a high index of suspicion
for benign causes, particularly if PET results show meta-
bolic remission of soft tissue and/or nodal disease. In such
cases, an additional bone marrow scan, such as a white
cell scan or a Tc-99m sulphur colloid scan [17], may be
useful in differentiating benign regenerating marrow from
true disease progression.
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